Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033, United States
NCT Number: NCT02712853
The goal of this project is to identify specific miRNAs that are increased or decreased in the saliva of children with developmental delay and are useful for screening toddlers for ASD. Such a screening tool would improve the specificity of diagnosis, streamline referrals to developmental specialists, and expedite the arrangement of early intervention services.
Looking for future studies?
Notify Me18 month–6 year
All sexes
Observational
Hershey, Pennsylvania, 17033, United States
The central aim of this project is to characterize the expression of exosomal microRNA (miRNA) in children with autism spectrum disorder (ASD). Currently, the CDC estimates the prevalence of ASD in U.S. children to be 1 in 68. Yet, the biological causes, diagnosis, and treatment of this disease remain ambiguous. Growing evidence implicates a genetic role in ASD. miRNAs regulate genetic expression and are altered in lymphocytes, neurons and serum of patients with ASD. Recent studies of miRNAs have shown that they can be packaged into exosomal vessels and extruded from neurons as extracellular signaling tools. This knowledge provides a novel approach for examining the genetic regulation of the central nervous system.
We propose to measure the expression of extracellular miRNA in children with ASD. Expression levels of miRNA from blood and saliva will be compared between children with autism and normally developing controls. The goal of this study will be to identify genetic regulatory mechanisms involved in ASD and provide potential biomarkers for diagnostic screening.
The primary endpoints of this study are as follows:
Secondary endpoints include the identification of miRNA expression patterns that correlate with ASD symptom severity measured with standardized neuropsychologic testing and to characterize parental knowledge and attitudes towards epigenetic testing in the context of ASD..
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
For autistic subjects study exclusion criteria will include:
Control subjects only exclusion criteria will include:
For both groups: wards of the state, active periodontal infection, active upper respiratory infection
Collection of saliva via swab for miRNA processing
Time frame: at time of collection (between 18 months and 6 years of age)
Measures of miRNA abundance in saliva
Time frame: at time of enrollment (between 18 months and 6 years)
Vineland adaptive behavior composite score
Time frame: at time of enrollment (between 18 months and 6 years)
Autism Diagnostic Observation Schedule (ADOS) Composite Score (when clinically indicated)
Milton S. Hershey Medical Center
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02769949
Asperger Disorder, Asperger Syndrome
Bethesda, Maryland, United States
View Trial DetailsNCT05675371
Autism, Autism Spectrum Disorder
Phoenix, Arizona, United States
View Trial DetailsNCT02832557
Asperger Syndrome, Autism Spectrum Disorder
Syracuse, New York, United States
View Trial DetailsNCT03847337
Autism Spectrum Disorder, Child Development Disorders, Pervasive
Nashville, Tennessee, United States
View Trial Details